UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Drug resistant TB - latest developments in epidemiology, diagnostics and management

Tiberi, Simon; Utjesanovic, Natasa; Galvin, Jessica; Centis, Rosella; D'Ambrosio, Lia; van den Boom, Martin; Zumla, Alimuddin; (2022) Drug resistant TB - latest developments in epidemiology, diagnostics and management. International Journal of Infectious Diseases 10.1016/j.ijid.2022.03.026. (In press). Green open access

[thumbnail of 1-s2.0-S1201971222001655-main.pdf]
Preview
Text
1-s2.0-S1201971222001655-main.pdf - Published Version

Download (935kB) | Preview

Abstract

AIM: The aim of this review is to inform the reader on the latest developments in epidemiology, diagnostics and management. EPIDEMIOLOGY: Drug-resistant Tuberculosis (DR-TB) continues to be a current global health threat, and is defined by higher morbidity and mortality, sequelae, higher cost and complexity. The WHO classifies drug-resistant TB into 5 categories: isoniazid-resistant TB, rifampicin resistant (RR)-TB and MDR-TB, (TB resistant to isoniazid and rifampicin), pre-extensively drug-resistant TB (pre-XDR-TB) which is MDR-TB with resistance to a fluoroquinolone and finally XDR-TB that is TB resistant to rifampicin, plus any fluoroquinolone, plus at least one further priority A drug (bedaquiline or linezolid). Of 500,000 estimated new cases of RR-TB in 2020, only 157 903 cases are notified. Only about a third of cases are detected and treated annually. DIAGNOSTICS: Recently newer rapid diagnostic methods like the GeneXpert, whole genome sequencing and Myc-TB offer solutions for rapid detection of resistance. TREATMENT: The availability of new TB drugs and shorter treatment regimens have been recommended for the management of DR-TB. CONCLUSION: Despite advances in diagnostics and treatments we still have to find and treat two thirds of the drug resistant cases that go undetected and therefore go untreated each year. Control of TB and elimination will only occur if cases are detected, diagnosed and treated promptly.

Type: Article
Title: Drug resistant TB - latest developments in epidemiology, diagnostics and management
Location: Canada
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.ijid.2022.03.026
Publisher version: https://doi.org/10.1016/j.ijid.2022.03.026
Language: English
Additional information: © 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. Available under the Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) licence.
Keywords: Active TB drug safety monitoring (aDSM), Adherence, BPaL, Drug susceptibility testing (DST), Drug-resistant TB (DR-TB), Rehabilitation, Treatment Guidelines, Video Observed Therapy (VOT), WHO shorter oral regimen
UCL classification: UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL
URI: https://discovery.ucl.ac.uk/id/eprint/10146787
Downloads since deposit
15Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item